Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho
Avant Technologies (OTCQB: AVAI) and Austrianova launched joint venture Klothonova on Oct 21, 2025 to develop cell‑based therapies that overexpress the longevity protein Klotho.
R&D proof‑of‑concept produced genetically modified human cells that overproduce Klotho and, when encapsulated in Austrianova’s Cell‑in‑Box, produced similar protein levels to non‑encapsulated cells. The JV is equally owned and will advance a GMP‑grade human cell clone toward preclinical and clinical studies; Austrianova is requalifying its ISO9001:2015 GMP isolator and preparing required documentation. The JV cites a cell therapy market projection of about $44 billion.
Avant Technologies (OTCQB: AVAI) e Austrianova hanno lanciato una joint venture Klothonova il 21 ottobre 2025 per sviluppare terapie basate su cellule che sovraesprimono la proteina di longevità Klotho.
Il concetto dimostrativo di R&D ha prodotto cellule umane geneticamente modificate che producono in eccesso Klotho e, quando incapsulate nel Cell‑in‑Box di Austrianova, hanno prodotto livelli proteici simili a quelli delle cellule non incapsulate. La JV è di proprietà equa e avanzerà un clone cellulare umano conforme GMP verso studi preclinici e clinici; Austrianova sta riqualificando il suo isolatore GMP ISO9001:2015 e preparando la documentazione necessaria. La JV cita una proiezione di mercato per terapie cellulari di circa $440억.
Avant Technologies (OTCQB: AVAI) y Austrianova lanzaron la empresa conjunta Klothonova el 21 de octubre de 2025 para desarrollar terapias basadas en células que sobreexpresan la proteína de longevidad Klotho.
Un concepto de prueba de I+D produjo células humanas modificadas genéticamente que sobreproducen Klotho y, cuando se encapsulan en el Cell‑in‑Box de Austrianova, producen niveles de proteína similares a los de las células no encapsuladas. La JV es de propiedad igual y avanzará un clon humano de células con GMP hacia estudios preclínicos y clínicos; Austrianova está recalificando su aislador GMP ISO 9001:2015 y preparando la documentación requerida. La JV cita una proyección de mercado de terapias celulares de aproximadamente $440억.
Avant Technologies (OTCQB: AVAI)와 오스트리아노바(Austrianova)는 2025년 10월 21일 수명 연장 단백질 Klotho를 과발현하는 세포 기반 치료를 개발하기 위해 합작투자회사 Klothonova를 설립했습니다.
연구개발(R&D) 개념 증명은 Klotho를 과발현하는 유전자 변형 인간 세포를 생산했고, Austrianova의 Cell‑in‑Box에 캡슐화될 때 비캡슐화된 세포와 유사한 수준의 단백질을 생성했습니다. 이 합작회사는 동등하게 소유되며 GMP 등급의 인간 세포 클론을 전임상 및 임상 연구로 진행합니다; Austrianova는 ISO9001:2015 GMP 격리장치의 재인증을 진행하고 필요한 서류를 준비 중입니다. 합작회사는 약 $440억의 세포 치료 시장 전망을 인용합니다.
Avant Technologies (OTCQB: AVAI) et Austrianova ont lancé une coentreprise Klothonova le 21 octobre 2025 pour développer des thérapies à base de cellules qui sur‑expriment la protéine de longévité Klotho.
La preuve de concept en R&D a produit des cellules humaines génétiquement modifiées qui produisent en excès Klotho et, lorsqu'elles sont encapsulées dans le Cell‑in‑Box d'Austrianova, elles produisent des niveaux de protéine similaires à ceux des cellules non encapsulées. La JV est détenue de manière égale et fera progresser un clone cellulaire humain conforme GMP vers des études précliniques et cliniques ; Austrianova est en train de requalifier son isolateur GMP ISO 9001:2015 et de préparer la documentation requise. La JV cite une projection de marché des thérapies cellulaires d'environ $440억.
Avant Technologies (OTCQB: AVAI) und Austrianova haben am 21. Oktober 2025 ein Joint Venture Klothonova gegründet, um zellbasierte Therapien zu entwickeln, die das Langlebigkeitsprotein Klotho überexprimieren.
Der Forschungs‑ und Entwicklungsproof‑of‑concept produzierte genetisch veränderte menschliche Zellen, die Klotho überproduzieren, und wenn sie in Austrianovas Cell‑in‑Box eingeschlossen wurden, erzeugten sie ähnliche Proteinspiegel wie unverpackte Zellen. Die JV ist gleichberechtigt im Eigentum und wird eine GMP‑klare menschliche Zelllinie in Richtung präklinischer und klinischer Studien voranbringen; Austrianova qualifiziert seinen ISO9001:2015 GMP‑Isolator neu und bereitet erforderliche Dokumente vor. Die JV nennt eine Marktprognose für Zelltherapien von etwa $440억.
Antes Technologies (OTCQB: AVAI) و Austrianova أطلقا مشروعًا مشتركًا Klothonova في 21 أكتوبر 2025 لتطوير علاجات خلويّة تعبر عن بروتين طول العمر Klotho.
أنتج مفاهيم إثبات البحث والتطوير خلايا بشرية معدلة وراثيًا تزيد من إنتاج Klotho، وعندما تُغلف في Cell‑in‑Box الخاص بـ Austrianova، أفرزت مستويات بروتين مماثلة لتلك التي لدى الخلايا غير المغلفة. الشراكة مملوكة بالتساوي وستطور عَزْل خلية بشرية GMP نحو دراسات قبل السريرية والسريرية؛ تقوم Austrianova بإعادة تأهيل جهاز العزل GMP ISO 9001:2015 وإعداد الوثائق المطلوبة. تشير الشراكة إلى توقع سوق لعلاجات الخلايا بحوالي $440억.
Avant Technologies (OTCQB: AVAI) 与 Austrianova 于 2025 年 10 月 21 日联合成立合资企业 Klothonova，以开发过表达长寿蛋白 Klotho 的细胞基础治疗。
研发概念验证显示，经过基因改造的人类细胞能过量表达 Klotho，且在 Austrianova 的 Cell‑in‑Box 封装后，其蛋白水平与未封装的细胞相似。该合资企业平等持有，将把 GMP 级人类细胞克隆推进至前临床与临床研究；Austrianova 正重新认证其 ISO9001:2015 GMP 隔离器并准备所需文件。合资企业引用约 $440亿 的细胞治疗市场预测。
- Joint venture established with 50/50 ownership between Avant and SGAustria
- R&D proof‑of‑concept: genetically modified human cells overproduce Klotho
- Encapsulated cells produced similar Klotho levels to non‑encapsulated cells
- Austrianova preparing GMP isolator requalification (ISO9001:2015) for clinical grade production
- Program remains at R&D/preclinical transition; no clinical data or trial timelines disclosed
- Encapsulated cells in study described as non‑optimized, indicating further development required
- No commercial partnerships, revenue, pricing or explicit funding plans disclosed
The program's initial phase has focused on R&D based proof of concept studies. A population of genetically modified human cells has been generated by Austrianova and shown to over-produce the Klotho protein. These cells were then successfully encapsulated in Austrianova's proprietary Cell-in-Box technology and shown to produce similar amounts of the Klotho protein to that produced by non-encapsulated cells. Although non-optimized, the encapsulated cells used in the study demonstrate quite clearly the feasibility of using encapsulated cells to continuously produce the Klotho protein.
The next stage for the program is to move forward with a proprietary GMP grade human cell clone that will be used in preclinical and eventually clinical studies. In preparation for this next stage, Austrianova is conducting routine servicing and requalification on its already ISO9001:2015 compliant, state of the art GMP isolator and facility, and preparing the necessary documentation needed for the next steps of the program. These essential steps will ensure the reproducibility and safety of the Klotho protein-producing cell lines, laying a strong foundation for producing high-quality clinical-grade therapeutics.
"The R&D level proof of concept study provides a clear rationale for the program, giving a green light to move to GMP studies. In addition, the meticulous preparations of the GMP facility at Austrianova represent a foundational milestone in bringing Klotho-based therapies to patients who need them most," said Chris Winter, CEO of Avant Technologies. "By prioritizing GMP compliance from the outset, Klothonova is committed to delivering safe, effective treatments that could transform the landscape of age-related disease management."
Dr. Brian Salmons, CEO of Austrianova, added, "Once again our encapsulation technology has proven it is ideal for long term continuous production of yet another protein, in this case, Klotho. Our expertise in cell encapsulation combined with Avant's innovative vision makes this joint venture uniquely positioned for success. The preparations we are undertaking today ensure that every cell we produce meets the highest standards of quality and safety, accelerating our path toward clinical trials."
This development program builds on the joint venture agreement signed in September 2025, which established Klothonova as a
- https://www.biospace.com/press - releases/cell - therapy - market - size - uplifts - usd - 44 - 39 - bn - at - 22 https://www.biospace.com/press-releases/cell-therapy-market-size-uplifts-usd-44-39-bn-at-22-69-healthy-cagr-by-2034 69 - healthy - cagr - by - 2034
About Avant Technologies Inc.
Avant Technologies Inc. is dedicated to advancing health through strategic biotech partnerships, focusing on innovative cell-based therapies to combat chronic and age-related diseases and promote longevity.
About Austrianova (SGAustria Pte. Ltd.)
Austrianova, based in
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
info@avanttechnologies.com
Logo - https://mma.prnewswire.com/media/2370694/5574100/Avant_Technologies.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-austrianova-launch-klothonova-begin-developing-age-related-cellular-therapies-using-longevity-protein-klotho-302589994.html
SOURCE Avant Technologies Inc.
FAQ
What did Avant (AVAI) and Austrianova announce on October 21, 2025?
What evidence supports Klothonova's Klotho program for AVAI?
What are the next steps and timelines for AVAI's Klothonova program?
How is Austrianova preparing to support AVAI's clinical work for Klothonova?
Does the Klothonova announcement include commercial revenue or funding details for AVAI (AVAI)?
